Com mais de um século de histórico operacional, uma rede de distribuição global que alcança instituições de saúde em praticamente todos os países, e crescimento consistente de lucros, Becton Dickinson é uma blue chip confiável no espaço de tecnologia médica.
Becton Dickinson é uma Dividend Aristocrat com mais de 50 anos consecutivos de aumento de dividendos anuais, apoiada pela natureza não-discricionária de seus produtos de suprimentos médicos que geram fluxos de caixa estáveis em qualquer ambiente econômico.
Becton Dickinson fornece as seringas, agulhas, cateteres IV, sistemas diagnósticos e plataformas de gerenciamento de medicamentos que hospitais e clínicas em todo o mundo dependem diariamente, tornando-a uma ação de saúde indispensável.
Data updated Feb 15 · Source: Twelve Data
Becton Dickinson is a global medical technology leader specializing in medical devices, instrument systems, and reagents. The company holds dominant positions in syringes, needles, and diagnostic systems, providing a durable competitive moat. At a P/E of 12.65 with EPS of $13.90, BDX appears attractively valued relative to healthcare peers, though this may reflect market concerns about growth trajectory.
The bull case centers on BD's essential product portfolio, recurring revenue streams, and recent strong momentum " up 29% over six months with the stock trading well above its 50-day moving average. The planned separation of its Biosciences segment could unlock shareholder value.
However, the bear case is notable: the stock is down nearly 10% over five years, significantly underperforming the broader market. Integration challenges from the Alaris infusion pump recall and elevated debt from acquisitions remain headwinds. The dividend yield, while supported by a 50+ year growth streak, is modest. BD offers defensive healthcare exposure but has struggled to deliver meaningful capital appreciation, making it better suited for income-oriented, conservative portfolios.
Becton Dickinson (BDX) remains a cornerstone of the medical technology sector, providing essential consumables and diagnostic systems that create a wide economic moat. Currently trading significantly below its 52-week high and well under its 50-day moving average, the stock presents a potential value opportunity for contrarian investors. With a P/E ratio of approximately 13, BDX is priced attractively compared to historical norms and broader healthcare indices, suggesting the market has priced in significant pessimism. While the company faces near-term headwinds regarding margins and operational execution, its status as a Dividend Aristocrat underscores its financial resilience and long-term commitment to shareholder returns. For investors seeking a defensive healthcare play with reliable cash flows and limited downside risk at this valuation, BDX offers a compelling entry point, though patience may be required for a technical trend reversal.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Todo trader tem uma estratégia que parece ótima em sua cabeça. Backtesting é como você descobre se ela realmente funciona. Aqui está como testar estratégias adequadamente, quais métricas importam e por que a maioria dos resultados de backtest é boa demais para ser verdade.
Powered by Rexiew